Human multipotent mesenchymal stromal cells (MSCs) exhibit multilineage differentiation potential, support hematopoiesis, and inhibit proliferation and effector function of various immune cells. On the basis of these properties, MSC are currently under clinical investigation in a range of therapeutic applications including tissue repair and immune-mediated disorders such as graft-versus-host-disease refractory to pharmacological immunosuppression. Although initial clinical results appear promising, there are significant concerns that application of MSC might inadvertently suppress antimicrobial immunity with an increased risk of infection. We demonstrate here that on stimulation with inflammatory cytokines human MSC exhibit broad-spectrum antimicrobial effector function directed against a range of clinically relevant bacteria, protozoal parasites and viruses. Moreover, we identify the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) as the underlying molecular mechanism. We furthermore delineate significant differences between human and murine MSC in that murine MSC fail to express IDO and inhibit bacterial growth. Conversely, only murine but not human MSC express inducible nitric oxide synthase on cytokine stimulation thus challenging the validity of murine in vivo models for the preclinical evaluation of human MSC. Collectively, our data identify human MSC as a cellular immunosuppressant that concurrently exhibits potent antimicrobial effector function thus encouraging their further evaluation in clinical trials.
Introduction
Human multipotent mesenchymal stromal cells (MSCs) exhibit multilineage differentiation potential and support endogenous tissue regeneration and hematopoiesis. 1 In addition, they inhibit proliferation and effector function of various immune cells including T and B lymphocytes as well as natural killer cells, effects that were shown to be partly mediated by expression of the tryptophan (tryp) catabolizing enzyme indoleamine 2, 3-dioxygenase (IDO). 2, 3 On the basis of these properties, MSCs are under intensive preclinical and clinical investigation in different therapeutic applications including repair of bone defects, stroke and myocardial infarction. More recently, MSCs have also evoked considerable interest by clinicians aiming to develop novel approaches for the treatment of immunemediated disorders, such as graft rejection and graft-versus-host disease (GvHD) in the setting of allogeneic hematopoietic stem cell transplantation. 4, 5 Although in these indications initial clinical results of MSC administration look very promising, it remains a matter of much concern that clinical application of immunosuppressive MSCs might inadvertently inhibit antimicrobial immune responses with an increased risk of infection, in particular in profoundly immunosuppressed patients. 6 Indeed, some reports have indicated that MSCs are capable of suppressing pathogen-specific T-cell proliferation and effector function directed against herpesviruses in vitro. 7, 8 However, data on the direct interaction between MSCs and microbial pathogens are sparse. Here, we demonstrate for the first time that on stimulation with inflammatory cytokines IDO-positive human MSCs exhibit a cell autonomous, broad-spectrum antimicrobial effector function directed against clinically relevant bacteria, protozoal parasites and viruses. This is in stark contrast to murine MSCs that fail to express IDO following cytokine exposure and do not inhibit bacterial growth.
Materials and methods

Isolation, culture and characterization of human and murine marrow-derived MSCs
Bone marrow aspirates were obtained from volunteer donors who had provided informed consent. This procedure was approved by the institutional review board of the HeinrichHeine-University, Dü sseldorf, Germany. Primary human MSCs were generated from the mononuclear cell fraction of the bone marrow samples as previously described. 2 The resulting MSC preparations exhibited the prototypical antigen expression profile of human MSCs (that is, CD14, CD34 and CD45 negative; CD29, CD44, CD73/SH-3/4, CD90 and CD105/SH-2 positive) and under appropriate culture conditions differentiated into adipogenic, osteogenic and chondrogenic lineages. Human MSC lines from passages 3 to 8 were utilized for subsequent experiments.
Murine MSCs were established from bone marrow mononuclear cells of 8-12 weeks old C57BL/6 and BALB/c mice as previously described.
9,10 They were passaged in Dulbecco's modified Eagle's medium low-glucose/10% fetal calf serum with or without 10 ng/ml murine epidermal growth factor (R&D Systems, Minneapolis, MN, USA) and 1 ng/ml human platelet-derived growth factor-BB (Peprotech, Abingdon, UK) according to standard protocols. Murine MSCs were used at passages 3-8 and were negative for CD34 and CD45 and stained positive for CD29, CD44, CD73/SH-3/4, CD90 and CD105 by flow cytometry. Multilineage differentiation potential of murine MSCs was verified utilizing standard assays for osteogenic, adipogenic and chondrogenic differentiation.
Detection of indoleamine IDO enzyme activity
MSCs (3 Â 10 4 per well) were stimulated for 72 h with increasing amounts of human or murine interferon-g (IFNg; R&D Systems) in the absence or presence of 100 U/ml interleukin-1b (IL1b; R&D Systems) and/or tumor necrosis factor-a (TNFa, Tebu-Bio, Offenbach, Germany). IDO enzyme activity was measured by tryp-to-kynurenine conversion with photometric determination of kynurenine concentration in the supernatant as the readout.
11
Detection of inducible nitric oxide synthetase (iNOS) enzyme activity
Nitrite accumulation in the supernatant of cultured cells was used as an indicator of NO production and was determined by the Griess reaction. 12 To this end, 3 Â 10 4 cells per well were incubated in the presence or absence of different cytokines in 96-well flat bottom microtiter plates for 24 h. In all, 100 ml of cell supernatant was used to perform the test and mixed with 100 ml Griess reagent (0.1% N-(1-naphtyl)ethylendiamin þ 2.5% sulfonamide in 15% HCl in a ratio of 1:1; Sigma-Aldrich, Deisenhofen, Germany). After an incubation time of 15 min, the absorbance was measured at 542 nm with a microplate reader (TECAN, Crailsheim, Germany). The amount of nitrite accumulation was determined using a calibration curve of graded concentrations of sodium nitrite.
Quantitative real-time PCR for human and murine IDO and iNOS transcripts
MSCs (1 Â 10 7 cells per 75 cm 2 flask) were stimulated with IFNg (25 ng/ml) alone or in combination with IL-1b (100 U/ml) and TNFa (100 U/ml) for 24 h. Unstimulated cells were used as a control. Total RNA was isolated from cells with Trizol reagent (Invitrogen, Karlsruhe, Germany) and chloroform and 1 mg of RNA was then subjected to complementary DNA synthesis utilizing Moloney murine leukemia virus reverse transcriptase. In all, 5 ml complementary DNA, 12.5 ml qPCR mastermix (Eurogentec, Seraing, Belgium), 0.25 mM of each primer (MWG, Ebersberg, Germany) and 0.2 mM of each Universal Probe Library probe (Roche, Mannheim, Germany) were mixed in a final volume of 25 ml and real-time PCR was performed with the iQ5 instrument (Bio-Rad, Munich, Germany). Sequences of primers were as follows: hu b-actin-forward 5 0 -ATTGGCAAT GAGCGGTTC-3 0 ; hu b-actin-reverse 5 0 -GGATGCCACAGG 
Western blot analysis for human and murine IDO and iNOS protein
MSCs stimulated for 24 h with IFNg (25 ng/ml) alone or in combination with IL-1b (100 U/ml) and TNFa (100 U/ml) were harvested and cell lysates were prepared. Separation of equal amounts of protein was performed by one-dimensional gel electrophoresis utilizing 10% NuPAGE Novex Bis-Tris Mini gels (Gibco Invitrogen, Karlsruhe, Germany). Following electrophoresis, the protein was transferred to nitrocellulose membranes (CarboGlas, Schleicher & Schü ll, Dassel, Germany). For immunodetection the following primary antibodies were employed: rabbit anti-human IDO polyclonal antibody (Chemicon, Schwalbach/Ts., Germany, 1:7500), rabbit antimurine IDO polyclonal antibody (Chemicon, 1:500), rabbit anti-human iNOS polyclonal antibody (Gibco Invitrogen, 1:2500), rabbit anti-murine iNOS polyclonal antibody (Calbiochem, Darmstadt, Germany, 1:2500) and murine anti-b-actin monoclonal antibody (clone AC-74, Sigma, 1:10 000). Goat anti-murine horseradish peroxidase-conjugated or goat anti-rabbit horseradish peroxidase-conjugated IgG (Jackson Immuno Research Laboratories, Dianova, Hamburg, Germany, 1:10 000-70 000) was used as the secondary antibody. Bound antibodies were visualized employing the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Freiburg, Germany).
Coculture of bacteria, Toxoplasma gondii and human cytomegalovirus with MSCs MSC (3 Â 10 4 per well) were prestimulated for 72 h with cytokines as described above and then inoculated with Staphylococcus aureus or Staphylococcus epidermidis (10-100 colony-forming units per well) as bacterial or Toxoplasma gondii tachyzoites (2 Â 10 4 per well) as prototypic protozoal pathogen. Bacterial growth was determined photometrically or via colony counting after 16 h of culture in the absence of any antibiotics 13 while Toxoplasma gondii proliferation in MSC was assessed via parasite-specific uptake of 3 H-uracil during the last 24 h of a 4-day culture period.
14 Moreover, human MSC monolayer cultures were infected with human cytomegalovirus (CMV) at an multiplicity of infection of 0.015 and viral replication was assessed by analysis of CMV genome copy number using quantitative PCR after 3 days of culture. Quantitative PCR was performed as previously described except that the following CMV-specific primers and detection reagents were used: CMV-forward 5
. 15 The role of IDO enzyme activity in cytokine-induced antimicrobial effector function was assessed via addition of the IDO-specific enzyme inhibitor 1-L-methyltryptophan (1-MT; final concentration 1.5 mM) or addition of excess amounts of tryp (final concentration 100 mg/ml; both from SigmaAldrich) to compensate for IDO-mediated depletion of its substrate tryp from the culture medium. The contribution of iNOS enzyme activity was analyzed utilizing the specific iNOS inhibitor N-methyl-L-arginine acetate (N G MMA; Sigma-Aldrich) at a final concentration of 100 mg/ml.
Statistical analysis
P-values were calculated using one-way or two-way analysis of variance as appropriate with Bonferroni correction for multiple testing. P-values o0.05 were considered to indicate statistical significance. For analysis of bacterial colony number and CMV genome copy number values were log-transformed before performing statistical analysis in order to approximate data to a Gaussian normal distribution. Conformity with normal distribution after log-transformation was verified using the Kolmogorov-Smirnov and Shapiro-Wilk normality tests. Figures show mean±s.e.m. values from the indicated number of individual experiments.
Results
On the basis of our previous identification of IDO as an IFNginducible T-cell inhibitory effector mechanism in human MSCs 2 and recent reports demonstrating antimicrobial activity of IDO expression in specific cell types 13, 15 we first investigated, whether pro-inflammatory tissue cytokines such as TNFa and IL1b could induce or enhance IDO expression in human MSCs. As single agents both cytokines failed to stimulate detectable amounts of IDO activity, yet they significantly potentiated IFNginduced IDO activity and this effect was most pronounced with TNFa (Supplementary Figure 1) . These data suggest that physiological levels of inflammatory cytokines induced by tissue damage and/or microbial infection are potent inducers of IDO enzyme activity in human MSCs.
In a next set of experiments, we investigated whether MSCs stimulated with IFNg alone or in combination with TNFa or IL1b would restrict the growth of bacterial pathogens. As shown in Figures 1a and b , we observed significant growth inhibition of both Staphylococcus aureus and Staphylococcus epidermidis bacteria when cultured in the presence of human MSC stimulated with IFNg, an effect that was significantly enhanced in the presence of TNFa (Figure 1a) . Notably, in the case of Staphylococcus epidermidis, a prototypic member of the group of coagulase-negative staphylococci, we found a 43-log reduction of bacterial growth quantified by enumeration of colony-forming units. In addition, we found comparable antibacterial effects in other clinically relevant bacteria such as Enterococcus faecium and group B streptococci (data not shown). Moreover, a similar antibacterial effect was observed when cell-free supernatant harvested from MSC cultures stimulated with IFNg was assessed for modulation of bacterial growth, while stimulation with TNFa or IL1b alone had no such effect (Supplementary Figure 2) . To elucidate, whether IDOdependent tryp catabolism is instrumental in cytokine-mediated inhibition of bacterial growth, we added the IDO-specific inhibitor 1-MT or excess amounts of tryp to our culture system. Under both conditions, we found a complete restoration of bacterial growth (Figures 1a and b) , thus identifying IDO-mediated tryp starvation as the main component of the underlying mechanism of the protective antimicrobial effect via two independent lines of experimental evidence. In a set of control experiments, we could not detect any impact of IFNg, IL1b and TNFa on bacterial proliferation in the absence of MSC (mean OD±s.e.m.: 0.591±0.071 (IFNg), 0.604±0.081 (IL1b), 0.607 ± 0.056 (TNFa) versus 0.581 ± 0.069 (medium control); P40.1; n ¼ 4), thus ruling out a direct effect of the respective cytokines on microbial growth. Similarly, the addition of excess amounts of tryp or the IDO inhibitor 1-MT did not alter bacterial growth in the absence of MSC (mean OD ± s.e.m.: 0.570 ± 0.085 (tryp), 0.582±0.085 (1-MT) versus 0.581±0.069 (medium control); P40.1; n ¼ 4).
We then proceeded to explore whether this MSC-mediated antimicrobial effector function also extends to other types of pathogens. Thus, human MSCs were infected with Toxoplasma gondii as an obligate intracellular parasite in the absence or presence of increasing amounts of IFNg. We observed a profound dose-dependent inhibitory effect of IFNg on toxoplasma growth, which was completely reversed by addition of supplementary tryp (Figure 1c) confirming that IDO-mediated tryp depletion indeed contributes to MSC-mediated antiparasitic effector function. As recent reports have demonstrated that MSCs might be target of infections with human herpesviruses representing prominent pathogens in the setting of allogeneic hematopoietic stem cell transplantation, 8, 16 we next investigated the potential impact of IDO-expression on replication of human CMV in MSCs. With increasing amounts of IFNg, we detected a 42.5-log decrease in CMV replication in MSC monolayer cultures as determined by quantitative PCR for CMV genome copy number after a 3-day culture period (Figure 1d) . Again, addition of the IDO-specific inhibitor 1-MT or excess amounts of tryp led to partial albeit significant restoration of CMV growth, thus indicating that IDO-mediated tryp catabolism is critically involved (Figure 1d) . Further analysis utilizing different infectious doses of CMV revealed that IDO-mediated inhibition of viral replication in human stromal cells, while observed at all doses of virus, is most pronounced at low compared with high multiplicities of infection (data not shown). Similar results were obtained for human herpes simplex virus type 1 as another member of the human herpes virus family (data not shown).
In view of future validation of the potential clinical relevance of these findings in murine in vivo models, we asked whether murine MSCs possess similar IDO-mediated antimicrobial effector functions. Murine MSCs lines were generated from C57BL/6 mice and exhibited the prototypic surface antigen profile and multilineage differentiation potential (data not shown). In contrast to their human counterparts, all murine MSC lines failed to express functional IDO enzyme activity, even under conditions of maximal cytokine stimulation, that is, high doses of IFNg in combination with TNFa and IL1b (Figure 2a ). Very recently, iNOS has been identified as a major mediator of inflammatory cytokine-induced immunosuppression in murine MSCs. 17, 18 Utilizing the same stimulatory conditions that had failed to induce IDO, we were able to detect significant iNOS enzyme activity in murine MSCs, thus ruling out insufficient cytokine stimulation as the reason for thè Murine and human MSCs were stimulated with TNFa and IL1b (100 U/ml each), IFNg (25 ng/ml) or a combination of all three cytokines. Cells cultured in cytokine-free medium served as negative control. After 3 days of culture, supernatant was harvested and IDO activity was measured by determining kynurenine concentration as absorbance (OD) at 492 nm (a). In parallel cultures, supernatant was collected after 24 h and iNOS activity was assessed by analysis of nitrate production as OD at 542 nm (b). (c) Murine MSCs stimulated with IFNg (25 ng/ml) alone or in combination with TNFa and IL1b (100 U/ml each) or cultured in medium without cytokines were inoculated with Staphylococcus aureus (Staph. aureus) or coagulase-negative staphylococci (Staphylococcus epidermidis; CNS) and bacterial growth was measured by determining bacterial density as absorbance (OD) at 620 nm. (d) Murine MSCs stimulated with IFNg (0.2 ng/ml) alone or in combination with TNFa and IL1b (100 U/ml each) or cultured in medium without cytokines were inoculated with Toxoplasma gondii tachyzoites and parasite proliferation in MSCs was assessed via parasite-specific uptake of 3 H-uracil. In parallel experiments, the iNOS-specific inhibitor N G MMA was added. Statistical significant differences between the indicated experimental conditions are presented with the respective P-values as calculated using one-way analysis of variance (ANOVA) with Bonferroni correction. Data from four to eight individual experiments, each performed in triplicates, are presented as mean values±s.e.m.
Antimicrobial effects of human multipotent mesenchymal stromal cellslack of IDO activity in murine MSCs (Figure 2b) . These findings were corroborated by analysis of IDO and iNOS mRNA and protein expression in murine MSCs (Figures 3a and c) . Comparable results were obtained with MSCs from BALB/c mice (Supplementary Figure 3) , thus arguing against a mouse strain-specific effect. Moreover, the presence of the growth factors epidermal growth factor and platelet derived growth factor-BB during MSC expansion had no effect on IDO and iNOS expression (data not shown). Of particular note, in the same set experiments, all human MSC lines failed to express iNOS enzyme activity on cytokine stimulation (Figure 2b ) and again this was substantiated by analysis of mRNA and protein expression (Figures 3b and d) .
In a final set of experiments, we then assessed the functional impact of these species-specific differences on the antimicrobial properties of murine compared with human MSCs. Corresponding to their failure to upregulate IDO enzyme activity and deplete tryp from the cellular microenvironment, cytokinestimulated murine MSCs proved unable to inhibit the bacterial growth of Staphylococcus aureus and CNS (Figure 2c ) and again the presence of epidermal growth factor and platelet derived growth factor-BB had no effect (data no shown). In contrast, under those stimulatory conditions inducing iNOS activity (that is, IFNg þ TNFa þ IL1b), the intracellular growth of Toxoplasma gondii parasites was attenuated in murine MSCs and this inhibitory effect was partially blocked by the iNOS-specific inhibitor N G MMA (Figure 2d ). These latter observations are in line with the previous identification of iNOS as a toxoplasmastatic effector mechanism in the mouse.
Discussion
In summary, our data provide evidence that IDO expression induced by inflammatory cytokines in human MSCs mediates potent antibacterial, antiprotozoal and antiviral effector functions. Hereby, we identify human MSCs as a promising cellular immunosuppressant that at the same time exhibits potentially beneficial antimicrobial properties. In addition, we delineate a notable species-specific difference between murine and human MSCs with regard to cytokine-inducible iNOS and IDO expression and antimicrobial effector function.
Regarding the apparently paradoxical inhibitory role of human MSCs on both microbial growth as well as antimicrobial T-cell responses, our group has recently shown that the degree of tryp depletion required for suppression of microbial growth is far less stringent than that required for T-cell inhibition. 19 Thus, one may speculate that during the early phase of an antimicrobial immune response IDO-mediated tryp depletion via MSCs will first impair microbial propagation while sparing antimicrobial immune responses. During the later stages of infection, however, progressive tryp depletion might finally lead to T-cell inhibition protecting the host from deleterious overreactivity of the immune system. However, a putative additional role of toxic tryp breakdown products in IDO-mediated T-cell inhibition remains a matter of scientific debate. As another aspect, preliminary experiments from our group indicate that CMV infection of human MSCs might substantially interfere with inflammatory cytokine-inducible IDO expression. Thus, the interplay between MSC-mediated antimicrobial effector function and immunomodulation is intricate and clearly warrants further experimental elucidation. Our identification of species-specific differences between murine and human MSCs with regard to cytokine-inducible iNOS and IDO expression as well as antimicrobial effects provides a cautionary note to the concept that any effects observed in murine models might be readily translated into the clinical setting and also imply that some biological features of human MSCs might only be delineated in a human in vitro system. In line with this, the results of our study also challenge the emerging concept that in humans iNOS has a pivotal role in MSC-mediated immunosuppression in vivo, 18 as in the human setting the role of IDO and others mechanisms appears more prominent. 2, [20] [21] [22] [23] In addition, the outlined functional differences between murine and human MSCs might provide a clue to the partially discrepant results on the therapeutic efficacy of MSC obtained in preclinical murine models [24] [25] [26] and clinical studies. 27 From a clinical perspective, the identification of a cell autonomous antimicrobial effector function in human MSCs is intriguing. In this respect, inducible bacterial growth inhibition by MSCs might prove most beneficial in tissue engineering approaches including bone regeneration or soft-tissue repair, where bacterial contamination at the site of surgical intervention, in particular infection with skin saprophytes such as Staphylococcus aureus and CNS, represents a major cause of treatment failure. 28, 29 Of particular interest, very promising data from a pilot study on the clinical use of MSCs in the treatment of steroid-induced avascular osteonecrosis have recently reported in this journal. 30 Antiprotozoal and antiviral effector functions of MSCs, however, appear more relevant in the setting of allogeneic hematopoietic stem cell transplantation where severe infections with herpesviruses and intracellular parasites such as Toxoplasma gondii have a prominent role. 31 This is particularly noteworthy as MSCs are preferentially utilized in those patients suffering from GvHD who have failed several lines of pharmacological immunosuppressive therapy and therefore are severely immunodeficient. Our findings may thus offer one explanation for the observations from very recent clinical studies with clear evidence for an in vivo immunosuppressive effect of MSC application without an indication for an increased risk for infection. 4, 27 Moreover, the recent notion that MSCs appear most valuable in the setting of severe intestinal GvHD might not only rely on their ability to support intestinal tissue regeneration and inhibit local T-cell proliferation. In this setting, MSCs may also exert beneficial effects via their selective homing to inflamed intestinal tissues and subsequent inhibition of microbial growth in the intestinal wall, which represents a key step in GvHD initiation and propagation. Thus, the inducible IDO-mediated dual antimicrobial and immunosuppressive effector functions of human MSCs clearly encourages further investigation of their potential therapeutic benefit in carefully designed clinical trials, as murine in vivo models appear to be insufficiently informative because of the outlined species-specific differences.
